CORALVILLE, Iowa –Vivakor, Inc. (OTCBB: VIVK) announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd. This agreement gives Pro Lab Marketing distribution rights for Vivakor’s VivaThermic cryovials in India. Pro Lab Marketing, based in New Delhi, is a well-established Indian supplier of biotechnology-related products and equipment throughout India. “We are impressed with the VivaThermic products and their outstanding performance,” stated Mr. J.K. Jain, Managing Director of Pro Lab Marketing. He continues, “Through our distribution agreement with Vivakor we will introduce the VivaThermic products to our customers throughout India who will benefit greatly from use of this technology.”

Vivakor’s CEO, Dr. Tannin Fuja, indicated that, “The Indian biotechnology industry is gaining significant momentum and India figures to become a prominent player in the global biotech market. A number of India’s biotech firms are beginning to emerge as major global players.” The budding of an innovative Indian biotech sector will hold major implications for the global industry and for improving both health and prosperity in the developing world.

Pro Lab Marketing, which distributes products for numerous reputable US and international manufacturers, supplies this growing Indian industry with equipment and supplies. A recent report, “Booming Biotech Market in India,” valued the Indian biotechnology market at US$ 2.86 Billion in 2007-08, and projects an annual growth rate of 30% in near future. The study also reports that Biopharma remains India’s biggest sector, accounting for nearly 70% of the total revenues in 2007-08 and is expected to be worth US$ 5.7 billion by 2012-2013. The future of the bio-supplier industry in India looks very bright and Vivakor is pleased to introduce its superior VivaThermic cryovials to its Indian customers through Pro Lab Marketing.

About Vivakor

Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor’s VivaThermic vials and their related market potential. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the SEC, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.